

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

NCT05223608

Status	RECRUITING
Phase	Not Applicable
Sponsor	Centre Oscar Lambret
Enrollment	651 participants

Key Eligibility Criteria

Inclusion (6)

- Age e 18 years
- Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
- In neo-adjuvant, adjuvant, recurrence or metastatic situation
- Suffering from solid tumor histologically documented
- Signed written informed consent
- ... and 1 more (see full listing online)

Exclusion (4)

- Pregnant or breastfeeding women
- Patient already treated by immunotherapy by immune checkpoint inhibitor
- Person under guardianship
- Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)

Locations (1 total)

Centre Oscar Lambret, Lille, Hauts-de-France, France